Iran to gain self-sufficiency in producing MS drug

TEHRAN (Tasnim) – A specific type of multiple sclerosis (MS) drug, called the BG-12, will be produced inside Iran within months, an official announced.


An Iranian pharmaceutical company is set to produce the BG-12 within the next two or three months, Hamid Reza Torabi, secretary of Iran’s 11th MS Congress said on Tuesday.

He also noted that Iran has made significant scientific progress in MS treatment in recent years.

Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision. It affects 2.5 million people worldwide and has no cure.

But fresh data from existing treatments and the arrival of new drugs is expected to transform the way doctors treat the disease and slow its progression. In the past, the severity of MS drugs’ side effects have led 35 to 40 percent of sufferers to opt for no treatment at all.

By Tasnim News Agency


The Iran Project is not responsible for the content of quoted articles.